期刊
CANCERS
卷 11, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/cancers11101521
关键词
aptamers; siRNA; miRNA; RNAi; shRNA; ASO; targeted delivery; cancer therapy; diagnosis; brain tumors
类别
资金
- Associazione Italiana Ricerca sul Cancro AIRC [18473]
- POR Campania FESR 2014-2020 SATIN grant
- European grant (H2020-MSCA-IF-2018) [838988]
- Fondazione Umberto Veronesi
- H2020-MSCA-RISE-2017 [777682-CANCER]
- Marie Curie Actions (MSCA) [838988] Funding Source: Marie Curie Actions (MSCA)
Due to the progress made in the area of precision and personalized medicine in the field of cancer therapy, strategies to selectively and specifically identify target molecules causative of the diseases are urgently needed. Efforts are being made by a number of different laboratories, companies, and researchers to develop therapeutic molecules that selectively recognize the tissues and the cells of interest, exhibit few or no off-target and side effects, are non-immunogenic, and have a strong action. Aptamers, artificially selected single-stranded DNA or RNA oligonucleotides, are promising molecules satisfying many of the requirements needed for diagnosis and precision medicine. Aptamers can also couple to their native mechanism of action the delivery of additional molecules (oligonucleotides, siRNAs, miRNAs) to target cells. In this review, we summarize recent progress in the aptamer-mediated strategy for the specific delivery of therapeutic oligonucleotides.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据